



Changes in Serum Level of Autotaxin with Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C as a Biomarker for Predicting Hepatic Fibrosis

Thesis

*Submitted for Partial Fulfillment
of Master Degree in Internal Medicine*

By

Basma Mohamad Mohamad Hassan

M.B.B.Ch, Ain Shams University

Supervised by

Prof. Dr. Engy Yousry ELsayed

*Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Asst. Prof. Dr. Hossam Samir ELbaz

*Assistant Professor of Internal Medicine and Gastroenterology
Faculty of Medicine - Ain Shams University*

Dr. Salah Shaarawy Galal

*Lecturer of Internal Medicine and Gastroenterology
Faculty of Medicine – Ain Shams University*

2019

Faculty of Medicine - Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Engy Yousry Elsayed**, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Asst. Prof. Dr. Hossam Samir Elbaz**, Assistant Professor of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Salah Shaarawy Galal**, Lecturer of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Basma Mohamad Mohamad Hassan

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations.....	10
Introduction.....	- 1 -
Aim of the Study	16
Review of Literature	
▪ Hepatitis C Virus.....	17
▪ The Process of Liver Fibrosis	34
▪ Serum Autotaxin as Abiomarker for Liver Fibrosis.....	78
▪ Direct Acting Antiviral Drugs (DAAs).....	92
Patients and Methods	130
Results	146
Discussion.....	168
Conclusion	175
Recommendations	176
Summary	177
References	179
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	METAVIR and Ishak staging systems for liver fibrosis.....	62
Table (2):	Non-invasive marker cut-offs for prediction of stages of fibrosis, including F3 (advanced fibrosis) and F4 (cirrhosis).....	101
Table (3):	HCV DAAs approved in Europe in 2018.....	107
Table (4):	IFN-free, ribavirin-free combination treatment regimens available for treatment naïve patients.....	108
Table (5):	Treatment recommendations for patients with chronic hepatitis C without cirrhosis, including treatment-naïve patients	109
Table (6):	Treatment recommendations for patients with chronic hepatitis C with compensated.....	110
Table (7):	Commonly used regimen of treatment for HCV by Egyptian national control program	129
Table (8):	Scoring.....	133
Table (9):	Interpretation.....	133
Table (10):	Materials supplied in the Test Kit.	136
Table (11):	Characteristics of studied subjects with regard to age.....	146
Table (12):	Characteristics of studied subjects with regard to gender.	147
Table (13):	Classification of studied subjects in fibrosis according to APRI and FIB 4.....	147
Table (14):	Comparison between patients before and 12weeks after treatment as regard CBC.	148
Table (15):	Comparison between patients before and 12 weeks post treatment as regard liver profile:	152
Table (16):	Fib-4 and APRI among the studied groups:.....	155
Table (17):	Serum autotaxin (mg/L) among the studied groups	157

List of Tables *cont...*

Table No.	Title	Page No.
Table (18):	Comparison in serum autotoxin levels (mg/L) before and 12 weeks post treatment as regard sex.	158
Table (19):	Comparison according to liver echogenicity regarding serum autotaxin (mg/L):.....	159
Table (20):	Correlations of serum autotoxin and characteristics of the patients:	160
Table (21):	Comparison among the studied cases before and 12weeks after treatment as regard liver fibrosis:	163
Table (22):	Comparison in liver fibrosis by APRI estimation before treatment regarding serum autotaxin (mg /L):.....	164
Table (23):	Diagnostic performance of serum autotaxin in predicting Fibrosis:.....	165
Table (24):	Comparison among the studied cases before and 12weeks after treatment as regard liver fibrosis according serum autotoxin:	165
Table (25):	Diagnostic characteristics of basal serum autotoxin ≥ 1.5 mg/L in predicting basal fibrosis:	167

List of Figures

Fig. No.	Title	Page No.
Figure (1):	HCV sources of transmission of infection by United States.	21
Figure (2):	Hepatitis C in Egypt.	27
Figure (3):	Transmission of HCV in Egypt among population.	28
Figure (4):	HCV genome.	29
Figure (5):	Mechanism of liver fibrosis.	35
Figure (6):	Liver regeneration and the epithelial to mesenchymal transition.	40
Figure (7)	: Hepatic stellate cells and liver fibrosis.	47
Figure (8):	The HCV-cAG.	52
Figure (9):	Viral Entry: target for antiviral therapy.	60
Figure (10):	Chronological events related the identifications of lysophosphatidic acid, ecto-nucleotide pyrophosphatase/ phosphodiesterase.	79
Figure (11):	Biochemical pathways of lysophosphatidic acid synthesis and degradation.	82
Figure (12):	Isoforms of serum autotoxin.	88
Figure (13):	Physiological role of serum Autotaxin.	89
Figure (14):	Therapeutic targets of the HCV replication cycle.	92
Figure (15):	Hemoglobin level 12 weeks post-treatment among the studied groups significantly decreased.	149
Figure (16):	Hemoglobin level 12weeks post-treatment among the studied groups significantly decreased.	149
Figure (17):	TLC among the studied groups before and 12 weeks post treatment not-significantly changed.	150

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure (18):	Platelets among the studied groups show increase in platelet 12 weeks post-treatment.....	150
Figure (19):	Platelets among the studied groups show increase in platelet 12 weeks post-treatment.....	151
Figure (20):	AST among the studied groups decrease 12 weeks post-treatment.....	153
Figure (21):	AST among the studied groups decrease 12 weeks post-treatment.....	153
Figure (22):	ALT among the studied groups decrease 12 weeks post- treatment.....	154
Figure (23):	ALT among the studied groups decrease 12 weeks post- treatment.....	154
Figure (24):	T.bilirubin among the studied groups non-significantly changed.....	155
Figure (25):	Fib-4 among the studied groups show significant decrease 12 weeks after the end of treatment.....	156
Figure (26):	APRI among the studied groups show significant decrease in ARI score before treatment and 12 weeks after.....	156
Figure (27):	Serum autotaxin among the studied groups show significant decrease of level before and 12 weeks after treatment.	157
Figure (28):	Comparison according to sex regarding serum autotoxin.	158
Figure (29):	Comparison according to liver echogenicity regarding serum autotoxin.....	159
Figure (30):	Correlations of baseline serum autotaxin and INR.	161
Figure (31):	Correlations of baseline serum autotaxin and PT.	161

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure (32):	Correlations of baseline serum autotaxin and Fib-4 score.	162
Figure (33):	Correlations of baseline serum autotaxin and APRI score.	162
Figure (34):	Liver fibrosis among the studied cases studied groups according APRI score.	163
Figure (35):	Comparison according to liver fibrosis before treatment regarding serum autotoxin.	164
Figure (36):	Liver fibrosis by serum autotaxin estimation among the studied cases.	166
Figure (37):	ROC curve basal serum autotaxin in predicting basal Fibrosis.	166
Figure (38):	Diagnostic characteristics of basal serum autotoxin ≥ 1.5 mg/L in predicting liver fibrosis.	167

List of Abbreviations

Abb.	Full term
<i>aa</i>	<i>Amino acid</i>
<i>ADAMTS2</i>	<i>A Disintegrin and Metalloproteinase with Thrombospondin type</i>
<i>apo</i>	<i>Apolipoprotein</i>
<i>apoB</i>	<i>Apolipoprotein B</i>
<i>apoE</i>	<i>Apolipoprotein</i>
<i>ATX</i>	<i>Autotaxin</i>
<i>BMI</i>	<i>Body mass index</i>
<i>CLDN1</i>	<i>Claudin-1</i>
<i>DAAs</i>	<i>Direct-acting antivirals</i>
<i>DALY</i>	<i>Disability-adjusted life years</i>
<i>DC-SIGN</i>	<i>Dendritic cell-specific intercellular adhesion molecule 3 grabbing non integrin</i>
<i>ECM</i>	<i>Extracellular MATRIX</i>
<i>EGF</i>	<i>Epidermal growth factor</i>
<i>Ennp</i>	<i>ecto-nucleotide pyrophosphatase / phosphodiesterase</i>
<i>GAG</i>	<i>Glycosaminoglycan</i>
<i>GGT</i>	<i>Glutamyltransferase</i>
<i>GPAT</i>	<i>Glycerophosphate acyltransferase</i>
<i>HAI</i>	<i>Histology activity index</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HCVcc</i>	<i>Cell culture-derived HCV</i>
<i>HCV-LP</i>	<i>HCV-like particles</i>
<i>HCVpp</i>	<i>HCV pseudoparticles</i>

List of Abbreviations *cont...*

Abb.	Full term
<i>HDL</i>	<i>High-density lipoprotein</i>
<i>HIV</i>	<i>Human immunodeficiency virus</i>
<i>HVR-11</i>	<i>Hypervariable region-1</i>
<i>LDL</i>	<i>Low-density lipoprotein</i>
<i>LDLR</i>	<i>LDL receptor</i>
<i>LPA</i>	<i>Lysophosphatidic acid</i>
<i>L-SIGN</i>	<i>DC-SIGNr, liver and lymph node specific</i>
<i>Lyso PLD</i>	<i>Lysophospholipase D</i>
<i>MAGK</i>	<i>Monoacylglycerol kinase</i>
<i>MELD</i>	<i>Model for End-Stage Liver Disease</i>
<i>MMPs</i>	<i>Matrix metalloproteinases</i>
<i>MOH</i>	<i>Egyptian Ministry of Health</i>
<i>MSM</i>	<i>Men who have sex with men</i>
<i>NIs</i>	<i>Nucleotide inhibitors</i>
<i>NNIs</i>	<i>Non-nucleotide inhibitors</i>
<i>NOS2</i>	<i>Nitric oxide synthase 2</i>
<i>NOX</i>	<i>NADPH oxidase</i>
<i>NUC</i>	<i>C-terminal nuclease-like</i>
<i>PAI-1</i>	<i>Plasminogen activator inhibitor 1</i>
<i>PDE</i>	<i>Phosphodiesterase</i>
<i>PDGF</i>	<i>Platelet-derived growth factor</i>
<i>PegIFN</i>	<i>Pegylated interferon</i>
<i>PI3Ks</i>	<i>Phosphoinositide 3-kinases</i>
<i>ROS</i>	<i>Reactive oxygen species</i>
<i>siRNA</i>	<i>Small interfering RNA</i>
<i>SMB</i>	<i>Somatomedin B-like</i>

List of Abbreviations *cont...*

Abb.	Full term
<i>SR-BI</i>	<i>Scavenger receptor class B type I</i>
<i>SVR</i>	<i>Sustained virological response</i>
<i>TE</i>	<i>Transient elastography</i>
<i>TGF-beta-1</i>	<i>Transforming growth factor beta-1</i>
<i>TIMPS</i>	<i>Metalloproteinases</i>
<i>UPA</i>	<i>Uroplasminogen activator</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>
<i>VLDL</i>	<i>Very low-density lipoprotein</i>
<i>WHO</i>	<i>World Health Organization</i>
<i>YLD</i>	<i>Years of life lost due to disability</i>
<i>YLL</i>	<i>Years of life lost due to premature death</i>

INTRODUCTION

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, Worldwide it is estimated that 185 million people are chronically infected with Hepatitis C virus (HCV), with 3-4 million new infections per year and over 350,000 deaths due to HCV-related liver disease each year (*Gower et al., 2016*).

The impact of HCV infection is highly variable, ranging from minimal effects to chronic hepatitis, advanced fibrosis, cirrhosis, decompensated cirrhosis and hepatocellular carcinoma. Chronic HCV infection may induce also severe extra-hepatic complications (*Maasoumy and Wedemeyer, 2016*).

The primary goal of HCV therapy is to cure the infection, i.e. to achieve a sustained virological response (SVR) defined as undetectable HCV RNA 12 weeks (SVR12) or 24 weeks (SVR24) after treatment completion. An SVR corresponds to a cure of the HCV infection, with a very low chance of late relapse (*Bruno et al., 2016*).

An SVR is generally associated with normalization of liver enzymes and improvement or disappearance of liver necro-inflammation and fibrosis in patients without cirrhosis. Patients with advanced fibrosis (METAVIR score F3) or cirrhosis (F4) remain at risk of life-threatening complications. However, hepatic fibro-sis may regress and the risk of

complications such as hepatic failure and portal hypertension is reduced after an SVR (*Nahon et al., 2017*).

Direct-acting antivirals (DAAs), the new interferon-free therapy, have been revolutionary in the treatment of hepatitis C. Previously, the disease was treated with pegylated interferon (PegIFN) combined with ribavirin. Direct-acting antivirals comprise four groups of medical substances which are mixed together (also with ribavirin) depending on the genotype of the hepatitis C virus and accompanying liver cirrhosis or other diseases. The groups are:

1. NS3/4A protease inhibitors – glecaprevir, paritaprevir, voxilaprevir, grazoprevir,
2. Nucleoside and nucleotide NS5B polymerase inhibitors – sofosbuvir,
3. NS5A inhibitors – ombitasvir, pibrentasvir, daclatasvir, elbasvir, ledipasvir, velpatasvir,
4. Non-nucleoside NS5B polymerase inhibitors – dasabuvir.

Invasive and noninvasive methods are used to monitor liver fibrosis. Invasive liver biopsies are difficult to undertake regularly because of the risk of bleeding, the length of hospitalization required to manage these risks, and the associated costs. Transient elastography (TE) and blood

sampling to determine the fibrosis marker levels are less-invasive liver fibrosis monitoring methods (*Wang et al., 2009*).

Autotaxin (ATX) is a secreted enzyme originally discovered in conditioned medium from A2058 human melanoma cell cultures. ATX has an important enzymatic function in converting lysophosphatidylcholine to lysophosphatidic acid (LPA), which has various physiological roles. LPA also stimulates the proliferation and contractility of hepatic stellate cells. ATX is present in serum and is metabolized by liver sinusoidal endothelial cells (*Reynaert et al., 2002*).

Liver fibrosis reduces the capacity to metabolize ATX, resulting in increases in the ATX level in serum. ATX has been shown to be useful as a serum marker for determining the fibrosis stage in CHC patients. In addition, ATX is suggested to be useful as an indicator of the severity of liver disease and for determining the prognosis of cirrhotic patients and HCC recurrence in combination with the levels of LPA receptors (*Enooku et al., 2016*).